An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: A subgroup analysis of patients with brain metastasis
Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), O. Dereure(Beth Israel Deaconess Medical Center), Sandrine Mansard(Centre Hospitalier Universitaire de Clermont-Ferrand), A. Szenik(Centre Hospitalier Universitaire de Besançon), Célèste Lebbé(Inserm), S. Dalac‐Rat(Centre Hospitalier du Mans), Thierry Lesimple, L. Machet(Université de Tours), Florent Grange(Centre Hospitalier Universitaire de Reims), Jean‐Jacques Grob, A. Denden(Novartis (France)), Laurent Mortier, Caroline Robert(Centre National de la Recherche Scientifique), H. Maillard(Université de Tours), C. Bédane(Central Michigan University), Eve‐Marie Neidhardt(Centre Léon Bérard), Charlée Nardin(CHU Dijon Bourgogne)
Cited by 1
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k